We rely on third parties to conduct our nonclinical studies and clinical trials, as well as for the manufacturing and supply of our product candidates and for the commercial supply of our products.
Arcutis Biotherapeutics, Inc. Customers
No clients on recordNo downstream customers found in our database for Arcutis Biotherapeutics, Inc..
Arcutis Biotherapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ARQT-DEBT
Debt stack $114.7M
90%
Market cache reports total debt of $114.7M.
ARQT-DEBT-7854
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
Arcutis Biotherapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Arcutis Biotherapeutics, Inc..
Arcutis Biotherapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
ARQT-OWNER-MORGAN-STANLEY
MORGAN STANLEY
90%
13F overlay lists MORGAN STANLEY as top holder; 272 tracked holders.
Arcutis Biotherapeutics, Inc. Extended Supply Chain Network